Argo Biopharma

News

Novartis is paying $160m upfront to activate an expanded R&D alliance with China's Argo Biopharma covering multiple cardiovascular disease drugs.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.